Tafinlar is an anti-cancer drug owned by Novartis. It contains dabrafenib mesylate as the active ingredient and was first authorized for market use on 29 May, 2013. It is available in capsule;oral dosage forms, and holds a total of 15 patents, none of which have expired yet.
The generics of Tafinlar are projected to be available after 29 June, 2038. This is determined by the expiry of the last patent held by the drug, which expires on this date.
Tafinlar is indicated for a range of uses owing to its active ingredient, dabrafenib mesylate. These include the treatment of patients with melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s), following complete resection, metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, low-grade glioma (LGG) in pediatric patients, locally advanced or metastatic anaplastic thyroid cancer (ATC), among others.
Tafinlar holds a total of 15 patents, with the last one set to expire on 29 June, 2038. This effectively determines the generic release date for Tafinlar. Some of the notable patents include those covering 'Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors', 'Method of adjuvant cancer treatment', 'Pharmaceutical composition', and 'Benzene sulfonamide thiazole and oxazole compounds'. Details of these patents are available below: